Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
264 Campbell et al.<br />
8. Barosi, G., Ambrosetti, A., Finelli, C., et al. (1999) The Italian Consensus Conference<br />
on Diagnostic Criteria for Myelofibrosis with <strong>Myeloid</strong> Metaplasia. Br. J.<br />
Haematol. 104, 730–737.<br />
9. Murphy, S., Peterson, P., Iland, H., and Laszlo, J. (1997) Experience of the Polycythemia<br />
Vera Study Group with essential thrombocythemia: a final report on<br />
diagnostic criteria, survival, and leukemic transition by treatment. Semin.<br />
Hematol. 34, 29–39.<br />
10. Pearson, T. C. (2001) Evaluation of diagnostic criteria in polycythemia vera.<br />
Semin. Hematol. 38, 21–24.<br />
11. Baxter, E. J., Scott, L. M., Campbell, P. J., et al. (2005) Acquired mutation of the<br />
tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–<br />
1061.<br />
12. James, C., Ugo, V., Le Couedic, J. P., et al. (2005) A unique clonal JAK2 mutation<br />
leading to constitutive signalling causes polycythaemia vera. Nature 434,<br />
1144–1148.<br />
13. Levine, R. L., Wadleigh, M., Cools, J., et al. (2005) Activating mutation in the<br />
tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid<br />
metaplasia with myelofibrosis. Cancer Cell 7, 387–397.<br />
14. Kralovics, R., Passamonti, F., Buser, A. S., et al. (2005) A gain-of-function mutation<br />
of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790.<br />
15. Scott, L. M., Campbell, P. J., Baxter, E. J., et al. (2005) The V617F JAK2 mutation<br />
is uncommon in cancers and in myeloid malignancies other than the myeloproliferative<br />
disorders. Blood, in press.<br />
16. Steensma, D. P., Dewald, G. W., Lasho, T. L., et al. (2005) The JAK2 V617F<br />
activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative<br />
disorders and the myelodysplastic syndrome. Blood, in press.<br />
17. el-Kassar, N., Hetet, G., Briere, J., and Grandchamp, B. (1997) Clonality analysis<br />
of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes<br />
and platelets. Blood 89, 128–134.<br />
18. Harrison, C. N., Gale, R. E., Machin, S. J., and Linch, D. C. (1999) A large proportion<br />
of patients with a diagnosis of essential thrombocythemia do not have a<br />
clonal disorder and may be at lower risk of thrombotic complications. Blood 93,<br />
417–424.<br />
19. Jones, A. V., Kreil, S., Zoi, K., et al. (2005) Widespread occurrence of the JAK2<br />
V617F mutation in chronic myeloproliferative disorders. Blood, in press.
Change language